TargetMol

Cenupatide

Product Code:
 
TAR-TP2338
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-TP2338-5mg5mg£193.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP2338-10mg10mg£275.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP2338-25mg25mg£441.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP2338-50mg50mg£773.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP2338-100mg100mg£1,272.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP2338-200mg200mg£1,936.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Cenupatide is a urokinase plasminogen activator receptor (uPAR) inhibitor. Cenupatide inhibits uPAR binding to the formyl peptide receptors (FPRs) can improve kidney lesions in a rat model of STZ-induced diabetes. Cenupatide reverted STZ-induced up-regulation of uPA levels and activity, while uPAR on podocytes and (s)uPAR were unaffected. In glomeruli, Cenupatide inhibited FPR2 expression.
CAS:
1006388-38-0
Formula:
C32H49F6N11O9
Molecular Weight:
845.802
Purity:
0.98
SMILES:
OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.CC(=O)N[C@@H](CCCNC(N)=N)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@](C)(Cc1ccccc1)C(N)=O

References

Cammalleri M, Locri F, Marsili S, Dal Monte M, Pisano C, Mancinelli A, Lista L, Rusciano D, De Rosa M, Pavone V, Bagnoli P. The Urokinase Receptor-Derived Peptide UPARANT Recovers Dysfunctional Electroretinogram and Blood-Retinal Barrier Leakage in a Rat Model of Diabetes. Invest Ophthalmol Vis Sci. 2017 Jun 1;58(7):3138-3148. doi: 10.1167/iovs.17-21593. PubMed PMID: 28632880. Boccella S, Panza E, Lista L, Belardo C, Ianaro A, De Rosa M, de Novellis V, Pavone V. Preclinical evaluation of the urokinase receptor-derived peptide UPARANT as an anti-inflammatory drug. Inflamm Res. 2017 Aug;66(8):701-709. doi: 10.1007/s00011-017-1051-5. Epub 2017 Apr 29. PubMed PMID: 28456844. Cammalleri M, Dal Monte M, Locri F, Marsili S, Lista L, De Rosa M, Pavone V, Rusciano D, Bagnoli P. Diabetic Retinopathy in the Spontaneously Diabetic Torii Rat: Pathogenetic Mechanisms and Preventive Efficacy of Inhibiting the Urokinase-Type Plasminogen Activator Receptor System. J Diabetes Res. 2017;2017:2904150. doi: 10.1155/2017/2904150. Epub 2017 Dec 31. PubMed PMID: 29464181; PubMed Central PMCID: PMC5804371. Dal Monte M, Cammalleri M, Pecci V, Carmosino M, Procino G, Pini A, De Rosa M, Pavone V, Svelto M, Bagnoli P. Inhibiting the urokinase-type plasminogen activator receptor system recovers STZ-induced diabetic nephropathy. J Cell Mol Med. 2018 Nov 13. doi: 10.1111/jcmm.14004. [Epub ahead of print] PubMed PMID: 30426662.